Role of Interleukin-13 in Cancer, Pulmonary Fibrosis, and Other TH2-Type Diseases

Vitamins and Hormones

Volumn 74, Issue , 2006, Pages 479-504

  Joshi, Bharat H ^a   Hogaboam, Cory ^b   Dover, Pamela ^a   Husain, Syed R ^a   Puri, Raj K ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 13;

ANIMAL; HUMAN; IMMUNOLOGY; IMMUNOPATHOLOGY; LUNG FIBROSIS; MOUSE; NEOPLASM; REVIEW; TH2 CELL;

ANIMALS; HUMANS; IMMUNE SYSTEM DISEASES; INTERLEUKIN-13; MICE; NEOPLASMS; PULMONARY FIBROSIS; TH2 CELLS;

EID: 33947723884     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0083-6729(06)74019-5     Document Type: Review

References (126)

1. Aman M.J., Tayebi N., Obiri N.I., Puri R.K., Modi W.S., and Leonard W.J. cDNA cloning and characterization of the human interleukin 13 receptor alpha chain. J. Biol. Chem. 271 (1996) 29265-29270
2. Aversa G., Punnonen J., Cocks B.G., de Waal Malefyt R., Vega Jr. F., Zurawski S.M., Zurawski G., and de Vries J.E. An interleukin 4 (IL-4) mutant protein inhibits both IL-4 or IL-13-induced human immunoglobulin G4 (IgG4) and IgE synthesis and B cell proliferation: Support for a common component shared by IL-4 and IL-13 receptors. J. Exp. Med. 178 (1993) 2213-2218
3. Backman K.S., Greenberger P.A., and Patterson R. Airways obstruction in patients with long-term asthma consistent with 'irreversible asthma.'. Chest 112 (1997) 1234-1240
4. Blease K., Jakubzick C., Schuh J.M., Joshi B.H., Puri R.K., and Hogaboam C.M. IL-13 fusion cytotoxin ameliorates chronic fungal-induced allergic airway disease in mice. J. Immunol. 167 (2001) 6583-6592
5. Blease K., Jakubzick C., Westwick J., Lukacs N., Kunkel S.L., and Hogaboam C.M. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J. Immunol. 166 (2001) 5219-5224
6. Blease K., Schuh J.M., Jakubzick C., Lukacs N.W., Kunkel S.L., Joshi B.H., Puri R.K., Kaplan M.H., and Hogaboam C.M. Stat6-deficient mice develop airway hyperresponsiveness and peribronchial fibrosis during chronic fungal asthma. Am. J. Pathol. 160 (2002) 481-490
7. Blease K., Lewis A., and Raymon H.K. Emerging treatments for asthma. Expert Opin. Emerg. Drugs 8 (2003) 71-81
8. Brombacher F. The role of interleukin-13 in infectious diseases and allergy. Bioessays 22 (2000) 646-656
9. Brown K.D., Zurawski S.M., Mosmann T.R., and Zurawski G. A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J. Immunol. 142 (1989) 679-687
10. Brubaker J.O., and Montaner L.J. Role of interleukin-13 in innate and adaptive immunity. Cell Mol. Biol. (Noisy-le-grand) 47 (2001) 637-651
11. Caput D., Laurent P., Kaghad M., Lelias J.M., Lefort S., Vita N., and Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J. Biol. Chem. 271 (1996) 16921-16926
12. Cocks B.G., de Waal Malefyt R., Galizzi J.P., de Vries J.E., and Aversa G. IL-13 induces proliferation and differentiation of human B cells activated by the CD40 ligand. Int. Immunol. 5 (1993) 657-663
13. Croteau D., Kunwar S., Ram Z., Sampson J.H., Prados M., Chang S.M., Lang F., Piepmeier J., Gutin P., Sherman J., Dul J., Grahn A., et al. A cytokine Tumor Targeting Agent, IL-13PE38QQR (Cintredekin Besudotox), Administered by Intraparenchymal Convection-Enhanced delivery (CED) for the Treatment of Recurrent Malignant Glioma (MG) Brain Tumors. Presented at Cytokines and Inflammation, San Diego, CA (2006)
14. Daines M.O., and Hershey G.K. A novel mechanism by which interferon-gamma can regulate interleukin (IL)-13 responses. Evidence for intracellular stores of IL-13 receptor alpha-2 and their rapid mobilization by interferon-gamma. J. Biol. Chem. 277 (2002) 10387-10393
15. D'Andrea A., Ma X., Aste-Amezaga M., Paganin C., and Trinchieri G. Stimulatory and inhibitory effects of interleukin (IL)-4 and IL-13 on the production of cytokines by human peripheral blood mononuclear cells: Priming for IL-12 and tumor necrosis factor alpha production. J. Exp. Med. 181 (1995) 537-546
16. David M., Bertoglio J., and Pierre J. TNF-alpha potentiates IL-4/IL-13-induced IL-13Ralpha2 expression. Ann. NY Acad. Sci. 973 (2002) 207-209
17. de Waal Malefyt R., Figdor C.G., Huijbens R., Mohan-Peterson S., Bennett B., Culpepper J., Dang W., Zurawski G., and de Vries J.E. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J. Immunol. 151 (1993) 6370-6381
18. de Waal Malefyt R., Abrams J.S., Zurawski S.M., Lecron J.C., Mohan-Peterson S., Sanjanwala B., Bennett B., Silver J., de Vries J.E., and Yssel H. Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int. Immunol. 7 (1995) 1405-1416
19. Debinski W., Obiri N.I., Pastan I., and Puri R.K. A novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin is highly cytotoxic to human carcinoma cells expressing receptors for interleukin 13 and interleukin 4. J. Biol. Chem. 270 (1995) 16775-16780
20. Debinski W., Obiri N.I., Powers S.K., Pastan I., and Puri R.K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer. Res. 1 (1995) 1253-1258
21. Debinski W., Miner R., Leland P., Obiri N.I., and Puri R.K. Receptor for interleukin (IL) 13 does not interact with IL4 but receptor for IL4 interacts with IL13 on human glioma cells. J. Biol. Chem. 271 (1996) 22428-22433
22. Defrance T., Carayon P., Billian G., Guillemot J.C., Minty A., Caput D., and Ferrara P. Interleukin 13 is a B cell stimulating factor. J. Exp. Med. 179 (1994) 135-143
23. Devouassoux G., Foster B., Scott L.M., Metcalfe D.D., and Prussin C. Frequency and characterization of antigen-specific IL-4- and IL-13-producing basophils and T cells in peripheral blood of healthy and asthmatic subjects. J. Allergy Clin. Immunol. 104 (1999) 811-819
24. Douglas W.W., Ryu J.H., and Schroeder D.R. Idiopathic pulmonary fibrosis: Impact of oxygen and colchicine, prednisone, or no therapy on survival. Am. J. Respir. Crit. Care Med. 161 (2000) 1172-1178
25. Doyle A.G., Herbein G., Montaner L.J., Minty A.J., Caput D., Ferrara P., and Gordon S. Interleukin-13 alters the activation state of murine macrophages in vitro: Comparison with interleukin-4 and interferon-gamma. Eur. J. Immunol. 24 (1994) 1441-1445
26. Fichtner-Feigl S., Strober W., Kawakami K., Puri R.K., and Kitani A. IL-13 signaling through the IL-13alpha(2) receptor is involved in induction of TGF-beta(1) production and fibrosis. Nat. Med. 12 (2006) 99-106
27. Fuss I.J., Heller F., Boirivant M., Leon F., Yoshida M., Fichtner-Feigl S., Yang Z., Exley M., Kitani A., Blumberg R.S., Mannon P., and Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113 (2004) 1490-1497
28. Gonzalez-Moreno O., Calvo A., Joshi B.H., Abasolo I., Leland P., Wang Z., Montuenga L., Puri R..K., and Green J.E. Gene expression profiling identifies IL-13 receptor alpha 2 chain as a therapeutic target in prostate tumor cells overexpressing adrenomedullin. Int. J. Cancer 114 (2005) 870-878
29. Grunig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., Sheppard D., Mohrs M., Donaldson D.D., Locksley R.M., and Corry D.B. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282 (1998) 2261-2263
30. Hampton J., Martinez F.J., Oren J., Toews G.B., and Lynch III J. Corticosteroids in idiopathic pulmonary fibrosis (IPF): Toxicity may outweigh benefits. Am. J. Respir. Crit. Care Med. 149 (1994) A878
31. Hasegawa M., Fujimoto M., Kikuchi K., and Takehara K. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J. Rheumatol. 24 (1997) 328-332
32. Hilton D.J., Zhang J.G., Metcalf D., Alexander W.S., Nicola N.A., and Willson T.A. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc. Natl. Acad. Sci. USA 93 (1996) 497-501
33. Hogaboam C.M., Blease K., Mehrad B., Steinhauser M.L., Standiford T.J., Kunkel S.L., and Lukacs N.W. Chronic airway hyperreactivity, goblet cell hyperplasia, and peribronchial fibrosis during allergic airway disease induced by Aspergillus fumigatus. Am. J. Pathol. 156 (2000) 723-732
34. Huang H., Hu-Li J., Chen H., Ben-Sasson S.Z., and Paul W.E. IL-4 and IL-13 production in differentiated T helper type 2 cells is not IL-4 dependent. J. Immunol. 159 (1997) 3731-3738
35. Husain S.R., and Puri R.K. Interleukin-13 fusion cytotoxin as a potent targeted agent for AIDS-Kaposi's sarcoma xenograft. Blood 95 (2000) 3506-3513
36. Husain S.R., and Puri R.K. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: From bench to bedside. J. Neuro-Oncology 65 (2003) 37-48
37. Husain S.R., Obiri N.I., Gill P., Zheng T., Pastan I., Debinski W., and Puri R.K. Receptor for interleukin 13 on AIDS-associated Kaposi's sarcoma cells serves as a new target for a potent Pseudomonas exotoxin-based chimeric toxin protein. Clin. Cancer Res. 3 (1997) 151-156
38. Husain S.R., Joshi B.H., and Puri R.K. Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int. J. Cancer 92 (2001) 168-175
39. Jakubzick C., Kunkel S.L., Joshi B.H., Puri R.K., and Hogaboam C.M. Interleukin-13 fusion cytotoxin arrests Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am. J. Pathol. 161 (2002) 1283-1297
40. Jakubzick C., Choi E.S., Joshi B.H., Keane M.P., Kunkel S.L., Puri R.K., and Hogaboam C.M. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J. Immunol. 171 (2003) 2684-2693
41. Jakubzick C., Choi E.S., Kunkel S.L., Joshi B.H., Puri R.K., and Hogaboam C.M. Impact of interleukin-13 responsiveness on the synthetic and proliferative properties of Th1- and Th2-type pulmonary granuloma fibroblasts. Am. J. Pathol. 162 (2003) 1475-1486
42. Jakubzick C., Choi E.S., Carpenter K.J., Kunkel S.L., Evanoff H., Martinez F.J., Flaherty K.R., Toews G.B., Colby T.V., Travis W.D., Joshi B.H., Puri R.K., et al. Human pulmonary fibroblasts exhibit altered interleukin-4 and interleukin-13 receptor subunit expression in idiopathic interstitial pneumonia. Am. J. Pathol. 164 (2004) 1989-2001
43. Jakubzick C., Choi E.S., Kunkel S.L., Evanoff H., Martinez F.J., Puri R.K., Flaherty K.R., Toews G.B., Colby T.V., Kazerooni E.A., Gross B.H., Travis W.D., et al. Augmented pulmonary IL-4 and IL-13 receptor subunit expression in idiopathic interstitial pneumonia. J. Clin. Pathol. 57 (2004) 477-486
44. Jakubzick C., Wen H., Matsukawa A., Keller M., Kunkel S.L., and Hogaboam C.M. Role of CCR4 ligands, CCL17 and CCL22, during Schistosoma mansoni egg-induced pulmonary granuloma formation in mice. Am. J. Pathol. 165 (2004) 1211-1221
45. Joshi B.H., and Puri R.K. Optimization of expression and purification of two biologically active chimeric fusion proteins that consist of human interleukin-13 and Pseudomonas exotoxin in Escherichia coli. Protein Expr. Purif. 39 (2005) 189-198
46. Joshi B.H., Kawakami K., Leland P., and Puri R.K. Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: Differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin. Cancer Res. 8 (2002) 1948-1956
47. Kawakami K., Joshi B.H., and Puri R.K. Sensitization of cancer cells to interleukin 13-pseudomonas exotoxin- induced cell death by gene transfer of interleukin 13 receptor alpha chain [In Process Citation]. Hum. Gene Ther. 11 (2000) 1829-1835
48. Kawakami K., Husain S.R., Bright R.K., and Puri R.K. Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts. Cancer Gene Ther. 8 (2001) 861-868
49. Kawakami K., Kawakami M., Joshi B.H., and Puri R.K. Interleukin-13 receptor-targeted cancer therapy in an immunodeficient animal model of human head and neck cancer. Cancer Res. 61 (2001) 6194-6200
50. Kawakami K., Kawakami M., Snoy P.J., Husain S.R., and Puri R.K. In vivo overexpression of IL-13 receptor alpha2 chain inhibits tumorigenicity of human breast and pancreatic tumors in immunodeficient mice. J. Exp. Med. 194 (2001) 1743-1754
51. Kawakami K., Taguchi J., Murata T., and Puri R.K. The interleukin-13 receptor alpha2 chain: An essential component for binding and internalization but not for interleukin-13-induced signal transduction through the STAT6 pathway. Blood 97 (2001) 2673-2679
52. Kawakami K., Husain S.R., Kawakami M., and Puri R.K. Improved anti-tumor activity and safety of interleukin-13 receptor targeted cytotoxin by systemic continuous administration in head and neck cancer xenograft model. Mol. Med. 8 (2002) 487-494
53. Kawakami M., Leland P., Kawakami K., and Puri R.K. Mutation and functional analysis of IL-13 receptors in human malignant glioma cells. Oncol. Res. 12 (2000) 459-467
54. Kawakami K., Kioi M., Liu Q., Kawakami M., and Puri R.K. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy. J. Immunother. 28 (2005) 193-202
55. Kawakami M., Kawakami K., and Puri R.K. Apoptotic pathways of cell death induced by an interleukin-13 receptor-targeted recombinant cytotoxin in head and neck cancer cells. Cancer Immunol. Immunother. 50 (2002) 691-700
56. Kawakami M., Kawakami K., and Puri R.K. Intratumor administration of interleukin 13 receptor-targeted cytotoxin induces apoptotic cell death in human malignant glioma tumor xenografts. Mol. Cancer Ther. 1 (2002) 999-1007
57. Kioi M., Kawakami K., and Puri R.K. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin. Clin. Cancer Res. 10 (2004) 6231-6238
58. Kioi M., Kawakami K., and Puri R.K. Mechanism of action of interleukin-13 antagonist (IL-13E13K) in cells expressing various types of IL-4R. Cell Immunol. 229 (2004) 41-51
59. Kitani A., Fuss I.J., Nakamura K., Schwartz O.M., Usui T., and Strober W. Treatment of experimental (Trinitrobenzene sulfonic acid) colitis by intranasal administration of transforming growth factor (TGF)-beta1 plasmid: TGF-beta1-mediated suppression of T helper cell type 1 response occurs by interleukin (IL)-10 induction and IL-12 receptor beta2 chain downregulation. J. Exp. Med. 192 (2000) 41-52
60. Kitani A., Fuss I., Nakamura K., Kumaki F., Usui T., and Strober W. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J. Exp. Med. 198 (2003) 1179-1188
61. Kohler I., Alliger P., Minty A., Caput D., Ferrara P., Holl-Neugebauer B., Rank G., and Rieber E.P. Human interleukin-13 activates the interleukin-4-dependent transcription factor NF-IL4 sharing a DNA binding motif with an interferon-gamma-induced nuclear binding factor. FEBS Lett. 345 (1994) 187-192
62. Kohler I., Alliger P., and Rieber E.P. Activation of gene transcription by IL-4, IL-13 and IFN-gamma through a shared DNA binding motif. Behring Inst. Mitt. 96 (1995) 78-86
63. Kolodsick J.E., Toews G.B., Jakubzick C., Hogaboam C., Moore T.A., McKenzie A., Wilke C.A., Chrisman C.J., and Moore B.B. Protection from fluorescein isothiocyanate-induced fibrosis in IL-13-deficient, but not IL-4-deficient, mice results from impaired collagen synthesis by fibroblasts. J. Immunol. 172 (2004) 4068-4076
64. Kotsimbos T.C., Ernst P., and Hamid Q.A. Interleukin-13 and interleukin-4 are coexpressed in atopic asthma. Proc. Assoc. Am. Physicians 108 (1996) 368-373
65. Krieg M., Marti H.H., and Plate K.H. Coexpression of erythropoietin and vascular endothelial growth factor in nervous system tumors associated with von Hippel-Lindau tumor suppressor gene loss of function. Blood 92 (1998) 3388-3393
66. Kunwar S., Pai L.H., and Pastan I. Cytotoxicity and antitumor effects of growth factor-toxin fusion proteins on human glioblastoma multiforme cells. J. Neurosurg. 79 (1993) 569-576
67. Kunwar S., Prados M., Lang F., Fleming C., Croteau D., Aldape K., Gutin P., Piepmeier J., Berger M.S., McDermott M., and Puri R. Intracerebal convection-enhanceddelivery (CED) of IL-13PE38QQR, a recombinant tumor-targeted cytotoxin, in recurrent malignant glioma in recurrent malignant glioma: A Phase I. Neuro-oncology 5 (2003) 387
68. Kunwar S., Prados M., Chang S.M., Lang F., Aldape K., Piepmeier J., Gutin P., Croteau D., and Puri R. Convection-Enhanced Delivery of IL-13PE38QQR: Results of a Multicenter Phase I study in Recurrent Malignant Glioma (2005), AANS, New Orleans, La Presented at
69. Kunwar S., Ram Z., Sampson J.H., Prados M., Chang S.M., Lang F., Piepmeier J., Gutin P., Croteau D., and Puri R. Peritumoral convection-enhanced delivery (CED) of IL-13PE38QQR (IL13PE): Results of multicenter phase 1 studies in recurrent high grade glioma (HGG). Neuro-oncology 7 (2005) 114
70. Kuwano K., Hagimoto N., and Hara N. Molecular mechanisms of pulmonary fibrosis and current treatment. Curr. Mol. Med. 1 (2001) 551-573
71. Kuzel T., Smith II J., Urba W., Fox B., Moudgil T., Strauss L., Joshi B., and Puri R. IL13-PE38QQR cytototxind in advanced renal cell carcinoma (RCC): Phase 1 and pharmacokinetic study. Presented at American Society of Clinical Oncology (ASCO), San Franscisco, CA (2002)
72. Kuznetsov V.A., and Puri R.K. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: Suppression of IL-13 binding by IL-2 receptor gamma chain. Biophys. J. 77 (1999) 154-172
73. Lang F., Kunwar S., Strauss L., Piepmeier J., McDermott M., Fleming C., Sherman J., Raizer J., Alalpe K., Yung W.K., Husain S.R., Chang S.M., et al. "A clinical study of convection-enhanced delivery of IL-13PE38QQR cytotoxin pre- and post-resection of recurrent GBM." (2002), American Society of Neuro-Oncologists, Chicago
74. Lasky J.A., and Brody A.R. Interstitial fibrosis and growth factors. Environ. Health Perspect. 108 Suppl. 4 (2000) 751-762
75. Lee C.G., Homer R.J., Zhu Z., Lanone S., Wang X., Koteliansky V., Shipley J.M., Gotwals P., Noble P., Chen Q., Senior R.M., and Elias J.A. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J. Exp. Med. 194 (2001) 809-821
76. Lee C.G., Cho S.J., Kang M.J., Chapoval S.P., Lee P.J., Noble P.W., Yehualaeshet T., Lu B., Flavell R.A., Milbrandt J., Homer R.J., and Elias J.A. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J. Exp. Med. 200 (2004) 377-389
77. Lin J.X., Migone T.S., Tsang M., Friedmann M., Weatherbee J.A., Zhou L., Yamauchi A., Bloom E.T., Mietz J., John S., and Leonard W.J. The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2 (1995) 331-339
78. Maini A., Hillman G., Haas G.P., Wang C.Y., Montecillo E., Hamzavi F., Pontes J.E., Leland P., Pastan I., Debinski W., and Puri R.K. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J. Urol. 158 (1997) 948-953
79. McKenzie A.N., Culpepper J.A., de Waal Malefyt R., Briere F., Punnonen J., Aversa G., Sato A., Dang W., Cocks B.G., Menon S., de Vries J.E., Banchereau J., et al. Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function. Proc. Natl. Acad. Sci. USA 90 (1993) 3735-3739
80. McKenzie G.J., Emson C.L., Bell S.E., Anderson S., Fallon P., Zurawski G., Murray R., Grencis R., and McKenzie A.N. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 9 (1998) 423-432
81. McKenzie G.J., Fallon P.G., Emson C.L., Grencis R.K., and McKenzie A.N. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J. Exp. Med. 189 (1999) 1565-1572
82. Mentink-Kane M.M., and Wynn T.A. Opposing roles for IL-13 and IL-13 receptor alpha 2 in health and disease. Immunol Rev. 202 (2004) 191-202
83. Minty A., Chalon P., Derocq J.M., Dumont X., Guillemot J.C., Kaghad M., Labit C., Leplatois P., Liauzun P., Miloux B., Minty C., Casellas P., et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362 (1993) 248-250
84. Murata T., and Puri R.K. Comparison of IL-13- and IL-4-induced signaling in EBV- immortalized human B cells. Cellullar Immunology 175 (1997) 33-40
85. Murata T., Noguchi P.D., and Puri R.K. Receptors for interleukin (IL)-4 do not associate with the common gamma chain, and IL-4 induces the phosphorylation of JAK2 tyrosine kinase in human colon carcinoma cells. J. Biol. Chem. 270 (1995) 30829-30836
86. Murata T., Noguchi P.D., and Puri R.K. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: Similarities between IL-4 and IL-13 signaling. J. Immunol. 156 (1996) 2972-2978
87. Murata T., Obiri N.I., and Puri R.K. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: Comparison between IL-4- and IL-13-induced signal transduction. Int. J. Cancer 70 (1997) 230-240
88. Murata T., Husain S.R., Mohri H., and Puri R.K. Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int. Immunol. 10 (1998) 1103-1110
89. Murata T., Obiri N.I., and Puri R.K. Structure of and signal transduction through interleukin-4 and interleukin-13 receptors (review). Int J Mol Med 1 (1998) 551-557
90. Obiri N.I., Debinski W., Leonard W.J., and Puri R.K. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J. Biol. Chem. 270 (1995) 8797-8804
91. Obiri N.I., Husain S.R., Debinski W., and Puri R.K. Interleukin 13 inhibits growth of human renal cell carcinoma cells independently of the p140 interleukin 4 receptor chain. Clin. Cancer Res. 2 (1996) 1743-1749
92. Obiri N.I., Leland P., Murata T., Debinski W., and Puri R.K. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J. Immunol. 158 (1997) 756-764
93. Obiri N.I., Murata T., Debinski W., and Puri R.K. Modulation of interleukin (IL)-13 binding and signaling by the gamma c chain of the IL-2 receptor. J. Biol. Chem. 272 (1997) 20251-20258
94. Ollerenshaw S.L., and Woolcock A.J. Characteristics of the inflammation in biopsies from large airways of subjects with asthma and subjects with chronic airflow limitation. Am. Rev. Respir. Dis. 145 (1992) 922-927
95. Parney I.F., Kunwar S., McDermott M., Berger M., Prados M., Cha S., Croteau D., Puri R.K., and Chang S.M. Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J. Neurosurg. 102 (2005) 267-275
96. Prados M., Lang F., Strauss L., Fleming C., Aldape K., Kunwar S., Yung W.K.A., Husain S.R., Chang S.M., Gutin P., Raizer J., Piepmeier J., et al. Pre and post-resection interstitial infusions of IL13-PE38QQR cytotoxin: Phase I study in recurrent respectable malignant glioma. Presented at First Quadrennial Meeting-World Federation of Neuro-Oncology, Washington, DC (2001)
97. Prados M., Lang F., Sherman J., Strauss L., Fleming C., Alalpe K., Kunwar S., Yung W.K., Chang S.M., Husain S.R., Gutin P., Raizer J., et al. Convection-enhanced delivery (CED) by positive pressure infusion for intra-tumoral and peri-tumoral administration of IL-13PE38QQR a recombinant tumor-targeted cytotoxin in recurrent malignant glioma. J. Neuro-Oncology 4 (2002) S78
98. Prados M., Lang F., Strauss L., Fleming C., Alalpe K., Kunwar S., Yung W.K., Chang S.M., Husain S.R., Gutin P., Raizer J., Piepmeier J., et al. Intratumoral and intracerebral microinfusion of Il13-PE38QQR cytotoxin: Phase I/II study of pre- and post-resection infusions in recurrent resectable malignant glioma. Am. Soc. Clin. Oncol (2002)
99. Prados M., Kunwar S., Lang F., Ram Z., Westphal M., Barnett G.H., Sampson J.H., Croteau D., and Puri R.K. Final results of PhaseI/II studies of IL-13PE38QQR administered intratumorally (IT) and/or peritumorally (PT) via convection-enhanced delivery (CED) in patients undergoing tumor resection for recurrent malignant glioma. J. Clin. Oncol. 23 (2005) 115S
100. Punnonen J., Aversa G., Cocks B.G., McKenzie A.N., Menon S., Zurawski G., de Waal Malefyt R., and de Vries J.E. Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells. Proc. Natl. Acad. Sci. USA 90 (1993) 3730-3734
101. Puri R.K., Leland P., Obiri N.I., Husain S.R., Kreitman R.J., Haas G.P., Pastan I., and Debinski W. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR). Blood 87 (1996) 4333-4339
102. Rahaman S.O., Sharma P., Harbor P.C., Aman M.J., Vogelbaum M.A., and Haque S.J. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells. Cancer Res. 62 (2002) 1103-1109
103. Rahaman S.O., Vogelbaum M.A., and Haque S.J. Aberrant Stat3 signaling by interleukin-4 in malignant glioma cells: Involvement of IL-13Ralpha2. Cancer Res. 65 (2005) 2956-2963
104. Ray A., and Cohn L. Th2 cells and GATA-3 in asthma: New insights into the regulation of airway inflammation. J. Clin. Invest. 104 (1999) 985-993
105. Ray A., and Cohn L. Altering the Th1/Th2 balance as a therapeutic strategy in asthmatic diseases. Curr. Opin. Investig. Drugs 1 (2000) 442-448
106. Ryu J.H., Colby T.V., and Hartman T.E. Idiopathic pulmonary fibrosis: Current concepts. Mayo Clin. Proc. 73 (1998) 1085-1101
107. Sampson J.H., Friedman A.H., Reardon D.A., Friedman H.S., Provenzale J.M., Bigner D.D., Brady M., Raghavan R., Pedain C., Archer G.E., Lally-Batts D., Grahan A., et al. Convection-Enhanced Delivery of IL-13PE38QQR in Malignant Glioma: Effect of Catheter Placement on Drug Distribution (2004)
108. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., Roberts A.B., Sporn M.B., and Thorgeirsson S.S. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA 92 (1995) 2572-2576
109. Smerz-Bertling C., and Duschl A. Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. J. Biol. Chem. 270 (1995) 966-970
110. Terabe M., Matsui S., Noben-Trauth N., Chen H., Watson C., Donaldson D.D., Carbone D.P., Paul W.E., and Berzofsky J.A. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol. 1 (2000) 515-520
111. Umetsu D.T., and De Kruyff R.H. Th1 and Th2 CD4+cells in the pathogenesis of allergic diseases. Proc. Soc. Exp. Biol. Med. 215 (1997) 11-20
112. Vita N., Lefort S., Laurent P., Caput D., and Ferrara P. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J. Biol. Chem. 270 (1995) 3512-3517
113. Weingart J., Grossman S.A., Bohan E., Fisher J.D., Strauss L., and Puri R.K. Phase I/II study of interstitial infusion of IL13-PE38QQR cytotoxin in recurrent malignant glioma. Presented at First Qudrennial Meeting-World Federation of Neuro-Oncology, Washington, DC (2001)
114. Weingart J., Strauss L., Grossman S.A., Markett J., Tatter S., Fisher J.D., Fleming C., and Puri R.K. Phase I/II study: Intra-tumoral infusion of IL13-PE38QQR cytotoxin for recurrent supratentorial malignat (2001)
115. Weingart J., Tatter S.S.R., Mikkelsen T., Barnett G., Fisher J., Grossman S.A., Croteau D., Grahan A., Sherman J., and Puri R. Intratumoral convection-enhanced delivery of IL-13PE38QQR cytototxin for recurrent malignant glioma without planned resection: A Phase I/II study. Presented at 8th Annual Meeting of the Society for Neuro-Oncology, Keystone, CO (2003)
116. Welham M.J., Learmonth L., Bone H., and Schrader J.W. Interleukin-13 signal transduction in lymphohemopoietic cells. Similarities and differences in signal transduction with interleukin-4 and insulin. J. Biol. Chem. 270 (1995) 12286-12296
117. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., and Donaldson D.D. Interleukin-13: Central mediator of allergic asthma. Science 282 (1998) 2258-2261
118. Wood N., Whitters M.J., Jacobson B.A., Witek J., Sypek J.P., Kasaian M., Eppihimer M.J., Unger M., Tanaka T., Goldman S.J., Collins M., Donaldson D., et al. Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor alpha 2. J. Exp. Med. 197 (2003) 703-709
119. Wynn T.A. IL-13 effector functions. Annu. Rev. Immunol. 21 (2003) 425-456
120. Yang G., Li L., Volk A., Emmell E., Petley T., Giles-Komar J., Rafferty P., Lakshminarayanan M., Griswold D.E., Bugelski P.J., and Das A.M. Therapeutic dosing with anti-interleukin-13 monoclonal antibody inhibits asthma progression in mice. J. Pharmacol. Exp. Ther. 313 (2005) 8-15
121. Yoshikawa M., Nakajima T., Tsukidate T., Matsumoto K., Iida M., Otori N., Haruna S., Moriyama H., and Saito H. TNF-alpha and IL-4 regulate expression of IL-13 receptor alpha2 on human fibroblasts. Biochem. Biophys. Res. Commun. 312 (2003) 1248-1255
122. Zhu Z., Homer R.J., Wang Z., Chen Q., Geba G.P., Wang J., Zhang Y., and Elias J.A. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest. 103 (1999) 779-788
123. Zund G., Madara J.L., Dzus A.L., Awtrey C.S., and Colgan S.P. Interleukin-4 and interleukin-13 differentially regulate epithelial chloride secretion. J. Biol. Chem. 271 (1996) 7460-7464
124. Zurawski G., and de Vries J.E. Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 12 (1994) 169-174
125. Zurawski G., and de Vries J.E. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15 (1994) 19-26
126. Zurawski S.M., Chomarat P., Djossou O., Bidaud C., McKenzie A.N., Miossec P., Banchereau J., and Zurawski G. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J. Biol. Chem. 270 (1995) 13869-13878